-
-
-
-
-
-
-
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
-
-
-
-
-
-
-
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
-
-
-
-
-
-
-
Barclays Starts Merck (MRK) at Overweight
-
-
-
-
-
-
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
-
-
-
-
-
-
Merck completes $10 billion acquisition of Verona Pharma
-
-
-
-
-
-
-
Merck (MRK) PT Lowered to $108 at Guggenheim
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
-
1,227,475 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

